Information  X 
Enter a valid email address

Idorsia Pharmaceuticals Ltd (0RQE)

  Print      Mail a friend

Saturday 31 August, 2019

Idorsia Pharmaceuticals Ltd

Phase 2 data of aprocitentan, Idorsia’s dual endothelin receptor antagonist, presented at ESC 2019


a d v e r t i s e m e n t